ZA200704910B - Pyrrolidine inhibitors of IAP - Google Patents

Pyrrolidine inhibitors of IAP

Info

Publication number
ZA200704910B
ZA200704910B ZA200704910A ZA200704910A ZA200704910B ZA 200704910 B ZA200704910 B ZA 200704910B ZA 200704910 A ZA200704910 A ZA 200704910A ZA 200704910 A ZA200704910 A ZA 200704910A ZA 200704910 B ZA200704910 B ZA 200704910B
Authority
ZA
South Africa
Prior art keywords
iap
inhibitors
pyrrolidine
pyrrolidine inhibitors
compounds
Prior art date
Application number
ZA200704910A
Other languages
English (en)
Inventor
Cohen Frederick
Tsui Vickie Hsiao-Wei
John A Flygare
Ly Cuong
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36129810&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200704910(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of ZA200704910B publication Critical patent/ZA200704910B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
ZA200704910A 2004-12-20 2005-12-19 Pyrrolidine inhibitors of IAP ZA200704910B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63820204P 2004-12-20 2004-12-20

Publications (1)

Publication Number Publication Date
ZA200704910B true ZA200704910B (en) 2008-09-25

Family

ID=36129810

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200704910A ZA200704910B (en) 2004-12-20 2005-12-19 Pyrrolidine inhibitors of IAP

Country Status (18)

Country Link
US (4) US20060167066A1 (enExample)
EP (1) EP1836201B2 (enExample)
JP (2) JP5007235B2 (enExample)
KR (2) KR20120127754A (enExample)
CN (1) CN101146803A (enExample)
AT (1) ATE477254T1 (enExample)
AU (1) AU2005319305B2 (enExample)
CA (1) CA2588921C (enExample)
DE (1) DE602005022936D1 (enExample)
DK (1) DK1836201T4 (enExample)
EA (1) EA019420B1 (enExample)
ES (1) ES2349110T5 (enExample)
IL (1) IL183514A (enExample)
MX (1) MX2007007195A (enExample)
NO (1) NO339157B1 (enExample)
NZ (1) NZ589670A (enExample)
WO (1) WO2006069063A1 (enExample)
ZA (1) ZA200704910B (enExample)

Families Citing this family (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1401850A1 (en) 2001-06-20 2004-03-31 Nuevolution A/S Nucleoside derivatives for library preparation
US7413854B2 (en) 2002-03-15 2008-08-19 Nuevolution A/S Method for synthesising templated molecules
US10730906B2 (en) 2002-08-01 2020-08-04 Nuevolutions A/S Multi-step synthesis of templated molecules
EP1558744B1 (en) 2002-10-30 2011-06-15 Nuevolution A/S Enzymatic encoding
WO2004056994A2 (en) 2002-12-19 2004-07-08 Nuevolution A/S Quasirandom structure and function guided synthesis methods
US20070026397A1 (en) 2003-02-21 2007-02-01 Nuevolution A/S Method for producing second-generation library
EP1670939B1 (en) 2003-09-18 2009-11-04 Nuevolution A/S A method for obtaining structural information concerning an encoded molecule and method for selecting compounds
RS52545B (sr) 2004-04-07 2013-04-30 Novartis Ag Inhibitori protein apoptoze (iap)
AU2005274937B2 (en) 2004-07-15 2011-08-18 Medivir Ab IAP binding compounds
KR20120127754A (ko) 2004-12-20 2012-11-23 제넨테크, 인크. Ｉａｐ의 피롤리딘 억제제
PL1851200T3 (pl) 2005-02-25 2014-06-30 Tetralogic Pharm Corp Dimeryczne inhibitory IAP
US7772177B2 (en) 2005-05-18 2010-08-10 Aegera Therapeutics, Inc. BIR domain binding compounds
WO2007003961A2 (en) * 2005-06-30 2007-01-11 Prosidion Limited Gpcr agonists
US20100256046A1 (en) * 2009-04-03 2010-10-07 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
DE102005046907A1 (de) 2005-09-30 2007-04-12 Voith Patent Gmbh Verfahren und Vorrichtung zur Herstellung einer Tissuebahn
WO2007048224A1 (en) 2005-10-25 2007-05-03 Aegera Therapeutics Inc. Iap bir domain binding compounds
EP2341140B1 (en) 2005-12-01 2017-07-19 Nuevolution A/S Enzymatic encoding methods for efficient synthesis of large libraries
AU2006340014B2 (en) 2005-12-19 2012-12-20 Genentech, Inc. Inhibitors of IAP
TWI543988B (zh) 2006-03-16 2016-08-01 科學製藥股份有限公司 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
AU2007250443B2 (en) 2006-05-16 2013-06-13 Pharmascience Inc. IAP BIR domain binding compounds
US20100056495A1 (en) * 2006-07-24 2010-03-04 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
WO2008014263A2 (en) 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap antagonists
US20100113326A1 (en) * 2006-07-24 2010-05-06 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
EP2049524A2 (en) 2006-07-24 2009-04-22 Tetralogic Pharmaceuticals Corporation Iap inhibitors
WO2008014229A2 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
PE20110217A1 (es) 2006-08-02 2011-04-01 Novartis Ag DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
CA2666112A1 (en) * 2006-10-12 2008-04-17 Novartis Ag Pyrrolydine derivatives as iap inhibitors
EP2125809A1 (en) * 2006-12-19 2009-12-02 Genentech, Inc. Imidazopyridine inhibitors of iap
JP5454943B2 (ja) 2007-04-12 2014-03-26 ジョイアント ファーマスーティカルズ、インク． 抗癌剤として有用なｓｍａｃ模倣二量体及び三量体
CL2008001234A1 (es) 2007-04-30 2008-09-22 Genentech Inc Compuestos derivados de heterociclos nitrogenados, inhibidores de las proteinas de apoptosis; y uso en el tratamiento del cancer.
EP2156189A1 (en) * 2007-05-07 2010-02-24 Tetralogic Pharmaceuticals Corp. Tnf gene expression as a biomarker of sensitivity to antagonists of inhibitor of apoptosis proteins
JP5176452B2 (ja) * 2007-09-27 2013-04-03 住友化学株式会社 光学活性なテトラヒドロピラニルグリシン化合物の製造方法
KR20100110870A (ko) * 2008-01-11 2010-10-13 제넨테크, 인크. Ｉａｐ의 억제제
WO2009094224A1 (en) 2008-01-25 2009-07-30 Millennium Pharmaceuticals, Inc. Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors
TW201011006A (en) * 2008-06-16 2010-03-16 Nuevolution As IAP binding compounds
AU2009279924B2 (en) 2008-08-02 2014-10-02 Genentech, Inc. Inhibitors of IAP
NZ590500A (en) * 2008-08-16 2012-06-29 Genentech Inc Azaindole inhibitors of iap
US9139589B2 (en) 2009-01-30 2015-09-22 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
RU2404166C1 (ru) * 2009-04-14 2010-11-20 Учреждение Российской Академии Наук Институт Нефтехимии И Катализа Ран Способ получения 1-ацетилизохинолина
US8283372B2 (en) * 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
WO2011016576A1 (en) 2009-08-04 2011-02-10 Takeda Pharmaceutical Company Limited Alanine derivatives as inhibitors of apoptosis proteins
AU2010283748A1 (en) 2009-08-12 2012-02-09 Novartis Ag Solid oral formulations and crystalline forms of an inhibitor of apoptosis protein
CN102612651A (zh) 2009-09-18 2012-07-25 诺瓦提斯公司 Iap抑制剂化合物的生物标志物
EP2493879B1 (en) 2009-10-28 2014-05-14 Joyant Pharmaceuticals, Inc. Dimeric smac mimetics
US8362068B2 (en) * 2009-12-18 2013-01-29 Idenix Pharmaceuticals, Inc. 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors
NZ602368A (en) 2010-02-12 2014-10-31 Pharmascience Inc Iap bir domain binding compounds
US11225655B2 (en) 2010-04-16 2022-01-18 Nuevolution A/S Bi-functional complexes and methods for making and using such complexes
WO2012021611A1 (en) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
CN103443068A (zh) 2011-03-22 2013-12-11 先正达参股股份有限公司 杀虫化合物
GB201106817D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compound
CN102757426A (zh) * 2011-04-28 2012-10-31 中国医学科学院医药生物技术研究所 一种苯并异恶唑基取代的噻唑类化合物、制备方法及用途
NO2755614T3 (enExample) * 2012-01-03 2018-03-31
HK1208875A1 (en) 2012-01-12 2016-03-18 耶鲁大学 Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an e3 ubiquitin ligase
WO2013166344A1 (en) 2012-05-04 2013-11-07 Novartis Ag Biomarkers for iap inhibitor therapy
GB201218850D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218864D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
US9980973B2 (en) 2012-10-19 2018-05-29 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
GB201218862D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
JP6587142B2 (ja) 2013-02-15 2019-10-09 国立大学法人 東京医科歯科大学 マイクロｒｎａからなるがん治療剤
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
EA035253B1 (ru) 2013-03-15 2020-05-21 Новартис Аг Лекарственные конъюгаты антител
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
CN105829310B (zh) 2013-12-20 2019-04-12 阿斯特克斯治疗有限公司 双环杂环化合物及其治疗用途
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
US10300074B2 (en) 2014-06-04 2019-05-28 Sanford Burnham Prebys Medical Discovery Institute Use of inhibitor of apoptosis protein (IAP) antagonists in HIV therapy
WO2016020791A1 (en) 2014-08-05 2016-02-11 Novartis Ag Ckit antibody drug conjugates
US10071164B2 (en) 2014-08-11 2018-09-11 Yale University Estrogen-related receptor alpha based protac compounds and associated methods of use
MA40513A (fr) 2014-08-12 2017-06-21 Novartis Ag Conjugués médicament-anticorps anti-cdh6
CA2974367A1 (en) 2015-01-20 2016-07-28 Arvinas, Inc. Compounds and methods for the targeted degradation of the androgen receptor
US12312316B2 (en) 2015-01-20 2025-05-27 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
US20180147202A1 (en) 2015-06-05 2018-05-31 Arvinas, Inc. TANK-BINDING KINASE-1 PROTACs AND ASSOCIATED METHODS OF USE
US20190194315A1 (en) 2015-06-17 2019-06-27 Novartis Ag Antibody drug conjugates
EP3337476A4 (en) 2015-08-19 2019-09-04 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
EP3535265A4 (en) 2016-11-01 2020-07-08 Arvinas, Inc. PROTACS TARGETING ON TAU PROTEIN AND RELATED METHODS FOR USE
RS64976B1 (sr) 2016-12-01 2024-01-31 Arvinas Operations Inc Derivati tetrahidronaftalena i tetrahidroizohinolina kao degradatori estrogenih receptora
RU2019121527A (ru) 2016-12-23 2021-01-15 Эрвинэс Оперейшнс, Инк. Химерные молекулы, нацеливающиеся на протеолиз egfr, и связанные с ними способы применения
WO2018118598A1 (en) 2016-12-23 2018-06-28 Arvinas, Inc. Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
JP7679173B2 (ja) 2016-12-23 2025-05-19 アルビナス・オペレーションズ・インコーポレイテッド Ｒａｆ（急速進行性線維肉腫）ポリペプチドの標的分解のための化合物および方法
US11173211B2 (en) 2016-12-23 2021-11-16 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
US11191741B2 (en) 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
CN117551089A (zh) 2017-01-26 2024-02-13 阿尔维纳斯运营股份有限公司 雌激素受体蛋白水解调节剂及相关使用方法
JOP20190187A1 (ar) 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7
EP3592868B1 (en) 2017-03-06 2022-11-23 Novartis AG Methods of treatment of cancer with reduced ubb expression
WO2018185618A1 (en) 2017-04-03 2018-10-11 Novartis Ag Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
MX2019014023A (es) 2017-05-24 2020-02-17 Novartis Ag Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer.
CN111107868A (zh) 2017-05-24 2020-05-05 诺华股份有限公司 抗体细胞因子移植蛋白及使用方法
WO2018215937A1 (en) 2017-05-24 2018-11-29 Novartis Ag Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
US20210371459A1 (en) * 2017-07-25 2021-12-02 Hepagene Therapeutics (HK) Limited Dimeric peptide inhibitors of apoptosis proteins
BR112020009369A2 (pt) 2017-11-13 2020-10-13 Chia Tai Tianqing Pharmaceutical Group Co., Ltd miméticos de smac usados como inibidores de iap e seus usos
WO2019099926A1 (en) 2017-11-17 2019-05-23 Arvinas, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
TWI812673B (zh) 2018-02-12 2023-08-21 美商富曼西公司 用於防治無脊椎害蟲之萘異噁唑啉化合物
JP7720698B2 (ja) 2018-04-04 2025-08-08 アルビナス・オペレーションズ・インコーポレイテッド タンパク質分解の調節因子および関連する使用方法
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
PL3820573T3 (pl) 2018-07-10 2024-02-19 Novartis Ag Pochodne 3-(5-hydroksy-1-oksoizoindolin-2-ylo)piperydyno-2,6-dionu i ich zastosowanie w leczeniu chorób zależnych od palca cynkowego z rodziny ikaros 2 (ikzf2)
WO2020023851A1 (en) 2018-07-26 2020-01-30 Yale University Bifunctional substitued pyrimidines as modulators of fak proteolyse
JP7297053B2 (ja) 2018-08-20 2023-06-23 アルビナス・オペレーションズ・インコーポレイテッド 神経変性疾患を治療するためのｅ３ユビキチンリガーゼ結合活性を有するキメラ（ｐｒｏｔａｃ）化合物を標的とし、アルファ－シヌクレインタンパク質を標的とするタンパク質分解
CN113164775B (zh) 2018-09-07 2025-03-18 阿尔维纳斯运营股份有限公司 用于迅速加速性纤维肉瘤多肽的靶向降解的多环化合物和方法
US20230053449A1 (en) 2018-10-31 2023-02-23 Novartis Ag Dc-sign antibody drug conjugates
CN113271945A (zh) 2018-12-20 2021-08-17 诺华股份有限公司 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案和药物组合
JP7607564B2 (ja) 2018-12-21 2024-12-27 ノバルティス アーゲー Ｐｍｅｌ１７に対する抗体及びその結合体
JP7483732B2 (ja) 2019-02-15 2024-05-15 ノバルティス アーゲー ３－（１－オキソ－５－（ピペリジン－４－イル）イソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
EP3924055B1 (en) 2019-02-15 2024-04-03 Novartis AG Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CN113543852A (zh) 2019-03-06 2021-10-22 第一三共株式会社 吡咯并吡唑衍生物
KR20220006611A (ko) * 2019-05-10 2022-01-17 치아타이 티안큉 파마수티컬 그룹 주식회사 Iap 억제제로서의 smac 모방물의 결정 및 그 제조방법
CN114867727B (zh) 2019-07-17 2025-02-21 阿尔维纳斯运营股份有限公司 Tau蛋白靶向化合物及相关使用方法
JP2022542437A (ja) 2019-08-02 2022-10-03 ランティオペプ ベスローテン ヴェンノーツハップ 癌の処置に用いるアンジオテンシン２型（ａｔ２）受容体アゴニスト
KR20220054347A (ko) 2019-08-26 2022-05-02 아비나스 오퍼레이션스, 인코포레이티드 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 유도체로 유방암을 치료하는 방법
TW202135859A (zh) 2019-12-20 2021-10-01 瑞士商諾華公司 組合療法
CN113354530B (zh) * 2020-03-07 2025-11-18 东莞市东阳光动物保健药品有限公司 一种制备4-乙酰基-1-萘甲酸的方法
HUP2200468A1 (hu) 2020-04-29 2023-03-28 X Chem Zrt IAP antagonisták és gyógyászati alkalmazásuk
US20230181756A1 (en) 2020-04-30 2023-06-15 Novartis Ag Ccr7 antibody drug conjugates for treating cancer
KR20230024967A (ko) 2020-06-11 2023-02-21 노파르티스 아게 Zbtb32 억제제 및 이의 용도
KR20230027056A (ko) 2020-06-23 2023-02-27 노파르티스 아게 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법
US20230271940A1 (en) 2020-08-03 2023-08-31 Novartis Ag Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
US12180193B2 (en) 2020-08-28 2024-12-31 Arvinas Operations, Inc. Accelerating fibrosarcoma protein degrading compounds and associated methods of use
JP2023541434A (ja) 2020-09-14 2023-10-02 アルビナス・オペレーションズ・インコーポレイテッド エストロゲン受容体の標的化分解のための化合物の結晶性形態
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
KR20230170738A (ko) 2021-04-16 2023-12-19 노파르티스 아게 항체 약물 접합체 및 이의 제조 방법
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
CN119301125A (zh) 2022-07-26 2025-01-10 诺华股份有限公司 Akr1c3依赖性kars抑制剂的晶型
US11957759B1 (en) 2022-09-07 2024-04-16 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use
KR20250151412A (ko) 2023-01-26 2025-10-21 아비나스 오퍼레이션스, 인코포레이티드 세레블론계 kras 분해 단백질 및 이와 관련된 용도

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE430062B (sv) 1977-03-04 1983-10-17 Pharmacia Fine Chemicals Ab Kopplings- eller tioleringsreagens
DE2714880A1 (de) * 1977-04-02 1978-10-26 Hoechst Ag Cephemderivate und verfahren zu ihrer herstellung
FR2575753B1 (fr) * 1985-01-07 1987-02-20 Adir Nouveaux derives peptidiques a structure polycyclique azotee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE3685626T2 (de) * 1985-09-26 1993-01-28 Beckmann Research Inst Of The Sequenzierung von peptiden.
US4935494A (en) * 1988-11-15 1990-06-19 City Of Hope C-terminal peptide and protein sequencing
CA2012306A1 (en) 1989-03-28 1990-09-28 Werner Neidhart Amino acid derivatives
DK167813B1 (da) * 1989-12-07 1993-12-20 Carlbiotech Ltd As Pentapeptidderivat, farmaceutisk acceptable salte heraf, fremgangsmaade til fremstilling deraf og farmaceutisk praeparat indeholdende et saadant derivat
WO1992001938A1 (en) 1990-07-20 1992-02-06 City Of Hope Derivatization of c-terminal proline
DE69303494T2 (de) 1992-11-13 1997-01-16 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5559209A (en) * 1993-02-18 1996-09-24 The General Hospital Corporation Regulator regions of G proteins
SK56798A3 (en) * 1995-10-30 1998-12-02 Smithkline Beecham Corp Protease inhibitors, pharmaceutical composition containing them and their use
WO1998046597A1 (en) 1997-04-14 1998-10-22 Emory University Serine protease inhibitors
US6335155B1 (en) 1998-06-26 2002-01-01 Sunesis Pharmaceuticals, Inc. Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
US6472172B1 (en) * 1998-07-31 2002-10-29 Schering Aktiengesellschaft DNA encoding a novel human inhibitor-of-apoptosis protein
EP1141708A1 (en) 1998-12-28 2001-10-10 Sunesis Pharmaceuticals Inc. Identifying small organic molecule ligands for binding
US6608026B1 (en) 2000-08-23 2003-08-19 Board Of Regents, The University Of Texas System Apoptotic compounds
CA2420534A1 (en) 2000-08-24 2002-02-28 Thomas Jefferson University An iap binding peptide or polypeptide and methods of using the same
WO2002026775A2 (en) 2000-09-29 2002-04-04 Trustees Of Princeton University Compositions and methods for regulating apoptosis
US6992063B2 (en) * 2000-09-29 2006-01-31 The Trustees Of Princeton University Compositions and method for regulating apoptosis
US7718600B2 (en) * 2000-09-29 2010-05-18 The Trustees Of Princeton University IAP binding compounds
WO2002096930A2 (en) 2001-05-31 2002-12-05 The Trustees Of Princeton University Iap binding peptides and assays for identifying compounds that bind iap
WO2002030959A2 (en) 2000-10-13 2002-04-18 Abbott Laboratories Peptides derived from smac (diablo) and methods of use therefor
AU2002253908A1 (en) 2001-02-08 2003-02-17 Thomas Jefferson University A conserved xiap-interaction motif in caspase-9 and smac/diablo for mediating apoptosis
EP1373263B1 (en) 2001-04-05 2004-10-27 Torrent Pharmaceuticals Ltd Heterocyclic compounds for aging-related and diabetic vascular complications
US20030157522A1 (en) * 2001-11-09 2003-08-21 Alain Boudreault Methods and reagents for peptide-BIR interaction screens
WO2003086470A2 (en) 2002-04-17 2003-10-23 Deutsches Krebsforschungszentrum Smac-peptides as therapeutics against cancer and autoimmune diseases
WO2004005248A1 (en) * 2002-07-02 2004-01-15 Novartis Ag Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)
WO2004017991A1 (en) 2002-08-13 2004-03-04 Cell Center Cologne Gmbh Use of iap for the diagnosis and of iap-inhibitors for the treatment of hodgkin’s lymphomas
US20040171554A1 (en) * 2003-02-07 2004-09-02 Genentech, Inc. Compositions and methods for enhancing apoptosis
JP4315249B2 (ja) 2003-02-07 2009-08-19 ジェネンテック・インコーポレーテッド アポトーシス亢進のための組成物と方法
IL156263A0 (en) 2003-06-02 2004-01-04 Hadasit Med Res Service Livin-derived peptides, compositions and uses thereof
AU2004291936A1 (en) 2003-11-13 2005-06-02 Burnham Institute Compositions and methods for screening pro-apoptotic compounds
CA2553874A1 (en) 2004-01-16 2005-08-04 The Regents Of The University Of Michigan Conformationally constrained smac mimetics and the uses thereof
US20100093645A1 (en) 2004-01-16 2010-04-15 Shaomeng Wang SMAC Peptidomimetics and the Uses Thereof
EP1723122B1 (en) 2004-03-01 2014-11-19 Board of Regents, The University of Texas System Dimeric small molecule potentiators of apoptosis
EP1740173A4 (en) 2004-03-23 2009-05-27 Genentech Inc AZABICYCLOOCTAN IAP INHIBITORS
RS52545B (sr) * 2004-04-07 2013-04-30 Novartis Ag Inhibitori protein apoptoze (iap)
PT1778718E (pt) 2004-07-02 2014-12-03 Genentech Inc Inibidores de iap
EA200700225A1 (ru) 2004-07-12 2008-02-28 Айдан Фармасьютикалз, Инк. Аналоги тетрапептида
AU2005274937B2 (en) 2004-07-15 2011-08-18 Medivir Ab IAP binding compounds
KR20120127754A (ko) 2004-12-20 2012-11-23 제넨테크, 인크. Ｉａｐ의 피롤리딘 억제제
PL1851200T3 (pl) * 2005-02-25 2014-06-30 Tetralogic Pharm Corp Dimeryczne inhibitory IAP
US7772177B2 (en) 2005-05-18 2010-08-10 Aegera Therapeutics, Inc. BIR domain binding compounds
WO2007048224A1 (en) * 2005-10-25 2007-05-03 Aegera Therapeutics Inc. Iap bir domain binding compounds
AU2006340014B2 (en) 2005-12-19 2012-12-20 Genentech, Inc. Inhibitors of IAP
US7205737B1 (en) 2006-01-04 2007-04-17 Robert Bosch Gmbh Systems and methods of monitoring a motor load
TWI543988B (zh) 2006-03-16 2016-08-01 科學製藥股份有限公司 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
CA2646186A1 (en) 2006-03-21 2007-11-29 Joyant Pharmaceuticals, Inc. Small molecule apoptosis promoters
CN101490100B (zh) 2006-04-07 2012-08-22 派奥特雷克株式会社 交联的硝基氧聚合物的制备方法
US20100143499A1 (en) 2006-07-24 2010-06-10 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
PE20110217A1 (es) 2006-08-02 2011-04-01 Novartis Ag DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2666112A1 (en) 2006-10-12 2008-04-17 Novartis Ag Pyrrolydine derivatives as iap inhibitors
EP2125809A1 (en) * 2006-12-19 2009-12-02 Genentech, Inc. Imidazopyridine inhibitors of iap
CL2008001234A1 (es) * 2007-04-30 2008-09-22 Genentech Inc Compuestos derivados de heterociclos nitrogenados, inhibidores de las proteinas de apoptosis; y uso en el tratamiento del cancer.
KR20100110870A (ko) * 2008-01-11 2010-10-13 제넨테크, 인크. Ｉａｐ의 억제제
AU2009279924B2 (en) * 2008-08-02 2014-10-02 Genentech, Inc. Inhibitors of IAP
NZ590500A (en) * 2008-08-16 2012-06-29 Genentech Inc Azaindole inhibitors of iap

Also Published As

Publication number Publication date
CA2588921A1 (en) 2006-06-29
US20090176822A1 (en) 2009-07-09
EP1836201B2 (en) 2013-09-04
EA019420B1 (ru) 2014-03-31
HK1109155A1 (en) 2008-05-30
IL183514A0 (en) 2007-09-20
AU2005319305B2 (en) 2012-08-23
IL183514A (en) 2015-11-30
NZ589670A (en) 2013-01-25
DE602005022936D1 (de) 2010-09-23
NO20073783L (no) 2007-09-19
AU2005319305A1 (en) 2006-06-29
JP2012184230A (ja) 2012-09-27
MX2007007195A (es) 2007-10-08
US20090318409A1 (en) 2009-12-24
ES2349110T5 (es) 2013-11-27
US8609845B2 (en) 2013-12-17
US20140080805A1 (en) 2014-03-20
CN101146803A (zh) 2008-03-19
NO339157B1 (no) 2016-11-14
ATE477254T1 (de) 2010-08-15
KR20070089174A (ko) 2007-08-30
DK1836201T3 (da) 2010-12-06
JP2008524333A (ja) 2008-07-10
KR101278732B1 (ko) 2013-07-09
EP1836201B1 (en) 2010-08-11
WO2006069063A1 (en) 2006-06-29
US20060167066A1 (en) 2006-07-27
KR20120127754A (ko) 2012-11-23
DK1836201T4 (da) 2013-11-11
ES2349110T3 (es) 2010-12-28
JP5007235B2 (ja) 2012-08-22
EP1836201A1 (en) 2007-09-26
CA2588921C (en) 2015-10-20
EA200701467A1 (ru) 2007-12-28
US9040706B2 (en) 2015-05-26

Similar Documents

Publication Publication Date Title
IL183514A0 (en) Pyrrolidine inhibitors of iap
WO2007106192A3 (en) Inhibitors of iap
WO2006028958A3 (en) Pyridyl inhibitors of hedgehog signalling
TW200942533A (en) Pyridyl inhibitors of hedgehog signalling
TW200634018A (en) Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and uses
IL177962A0 (en) Compounds and methods for treating dyslipidemia
UA84712C2 (en) N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors
IL185275A0 (en) N-sulphonylpyrrole derivatives and pharmaceutical compositions containing the same
MX2009003157A (es) Pirazoliltienopiridinas terapeuticas.
TW200640924A (en) VEGF-R2 inhibitors and methods
TW200745028A (en) Novel sulphonylpyrroles
PL1853602T3 (pl) Związki chemiczne
PT1853588E (pt) Compostos químicos
TW200510317A (en) Caspase inhibitors and uses thereof
TW200745027A (en) Novel sulphonylpyrroles
MX2010007543A (es) Inhibidores de iap.
ZA200801332B (en) Pentacyclic kinase inhibitors
TW200722427A (en) Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
TW200600499A (en) Novel amido-substituted hydroxy-6-phenylphenanthridines
WO2007120333A3 (en) Tetracyclic kinase inhibitors
MX2010010876A (es) Piperidinas sustituidas como compuestos terapeuticos.
TW200740781A (en) Novel compounds
TW200634013A (en) Quinoline derivative, its use, production and pharmaceutical agents containing the derivative
MXPA06000372A (es) Compuestos de silicio y su uso.
EA200701813A1 (ru) Новые амидозамещенные 6-фенилфенантридины